Broad-Spectrum Protective Effects of Lyophilized FE002-Lu Lung Fibroblast Conditioned Medium Against Acute and Chronic Pulmonary Injury in Wistar Rats

Our plain-English summary of Broad-Spectrum Protective Effects of Lyophilized FE002-Lu Lung Fibroblast Conditioned Medium Against Acute and Chronic Pulmonary Injury in Wistar Rats, by L.A. Applegate, A. Porcello, A.E. Laurent (Biomedicines, 2026).

The study

• Authors: L.A. Applegate, A. Porcello, A.E. Laurent
• Journal: Biomedicines
• Published: 2026;14(9)
• Read it: PubMed · Publisher · Free full text

Abstract

Background: While live-cell therapies face significant translational hurdles, cell-free secretomes derived from fetal progenitor cells offer a unique, scalable approach natively programmed for scarless tissue repair. Methods: This GLP-compliant study evaluated the therapeutic efficacy spectrum of an off-the-shelf, clinical-grade, intratracheal lyophilized FE002-Lu lung fibroblast conditioned medium (LFCM) across five controlled Wistar rat models of induced lung injury: bleomycin (5 mg/kg), asbestos (100 µg/rat), hyperoxia (100% oxygen exposure), silica (30 mg/rat), and lipopolysaccharide (LPS, 4 mg/kg). Following lung injury induction and symptom onset, symptomatic rats were randomized to receive intratracheal LFCM (low, mid, or high dose) or a vehicle control every 4 days for 28 days. Results: The intervention demonstrated an exceptional safety profile, maintaining 100% survival with no severe procedural toxicity across all cohorts. Across all study arms, LFCM effectively attenuated pulmonary inflammation, reducing pro-inflammatory markers (IL-1β, IL-6, TNF-α, and CINC-1) in bronchoalveolar lavage fluid. Concurrently, high LFCM doses consistently elevated the anti-inflammatory cytokine IL-10. Within the lung tissue, mid- and high doses significantly reduced key pro-fibrotic drivers, including TGF-β1, TIMP-1, WISP-1, and hydroxyproline. Treatments consistently decreased α-SMA expression and pro-fibrotic gene mRNA levels, mitigating pulmonary myofibroblast activation. This correlated with reduced Ashcroft scores and collagen deposition, thereby preserving lung architecture. Notably, the FE002-Lu LFCM treatment exerted a biphasic regulation of extracellular matrix turnover: it elevated Cathepsin-D and MMP-12 in the bleomycin arm to actively clear newly deposited fibrotic debris, while reducing these markers in the hyperoxia and LPS arms to prevent acute collateral degradation of the native lung matrix. In both particulate models (asbestos and silica), the LFCM mid-dose established an optimal therapeutic threshold, avoiding the localized secretome saturation and pro-fibrotic exacerbation occasionally observed at higher doses. Conclusions: Lyophilized FE002-Lu LFCM acts as a potent, pleiotropic biologic that effectively resolves acute pulmonary inflammation and arrests progressive fibrotic remodeling across multiple distinct in vivo models. By overcoming the cold-chain and delivery limitations inherent to pulmonary live-cell therapies, this stable, cell-free secretome represents a highly scalable, "off-the-shelf" candidate poised for non-invasive, aerosolized clinical translation.

In plain English

This was an animal experiment in male Wistar rats. It tested a freeze-dried liquid from cultured human fetal lung cells (FE002-Lu lung fibroblast conditioned medium) as a lung injury treatment. The authors studied five injury models of 40 rats each; one used a single 100 µg dose of chrysotile asbestos placed into the windpipe. Each model had five groups of 8: uninjured rats given saline, and symptomatic injured rats given saline or a low, mid, or high product dose every four days for 28 days. All rats survived. In asbestos-injured rats, the high dose lowered inflammation markers IL-1β and TNF-α and raised IL-10. The mid and high doses lowered tissue TIMP-1 and hydroxyproline. However, the high dose significantly increased lung scarring (Ashcroft) scores and collagen compared with saline-treated asbestos-injured rats. Low- and high-dose asbestos-injured rats weighed significantly less than saline-treated injured rats at several time points. The authors concluded that the mid dose gave the most balanced protection and the highest dose could worsen scarring with asbestos. They noted that only male rats were used and that the 28-day treatment window limited long-term assessment.

We wrote this plain-English summary from the full article with the help of AI, and a second AI model checked each sentence against the article. It is not the authors' wording; the abstract and the article are their own account.

What the study did and found

• Design: Animal experiment: randomized, controlled, multi-arm study in rats. There were five lung injury models, each with a sham group, a disease-control group and three treatment-dose groups.
• Who was studied: Healthy young adult male Wistar rats aged 9 to 11 weeks, 40 per study arm and 8 per group. The five arms were hyperoxia, LPS, asbestos, silica and bleomycin. The work was done at Trans-Genica Services, Maharashtra, India, under a protocol approved 4 April 2025.
• Exposure: In the asbestos arm, rats received a single dose of 100 µg chrysotile asbestos (approximate particle size 5 µm) in saline, placed into the windpipe. The other arms used 100% oxygen, LPS (4 mg/kg), crystalline silica (30 mg) or bleomycin (5 mg/kg). Treatment was 50 µL of the conditioned medium (low, mid or high dose) or saline vehicle, placed into the windpipe every four days over a 28-day treatment period. Uninjured sham rats received saline and no toxicant.
• Main results:
  • All rats in all five study arms survived the 28-day treatment period.
  • In the asbestos arm, the high-dose group had significantly lower IL-1β and TNF-α in lung lavage fluid than saline-treated asbestos-injured rats.
  • In the asbestos arm, IL-6 and CINC-1 were significantly reduced in the mid- and high-dose groups. IL-10 was significantly raised in the high-dose group.
  • In the asbestos arm, lung tissue TIMP-1 and hydroxyproline were significantly lower in the mid- and high-dose groups. WISP-1 was significantly lower only in the high-dose group.
  • In the asbestos arm, the high-dose group had a statistically significant increase in Ashcroft fibrosis scores and total collagen deposition compared with saline-treated asbestos-injured rats.
  • In the asbestos arm, the high-dose group showed a statistically significant increase in Cathepsin-D and α-SMA immunohistochemistry scores.
  • In the asbestos arm, the high-dose group showed mainly acute focal hemosiderin accumulation at autopsy. It lacked the dense fibrotic consolidation seen in the saline-treated asbestos controls.
  • In the asbestos arm, the low- and high-dose groups weighed significantly less than saline-treated asbestos-injured rats at several time points.
  • In the asbestos arm, blood white cell, lymphocyte and eosinophil counts rose significantly at all three doses compared with saline-treated asbestos-injured rats.
  • In the asbestos arm, platelets in lung lavage fluid were significantly reduced in the low- and mid-dose groups.
  • Ashcroft scores were significantly reduced in some treatment groups of the hyperoxia, LPS, silica and bleomycin arms, but not in the asbestos arm.
• The authors' conclusion: The authors concluded that the mid dose gave the most balanced protection. They also concluded that in the asbestos model the highest dose could paradoxically worsen fibroproliferation, and saw this as a key point for future dose-finding work.
• Limitations the authors state:
  • Only male rats were used.
  • The 28-day evaluation window does not allow assessment of long-term remodeling, late toxicity or relapse after treatment stops.
  • The rodent models do not fully replicate the slow, years-long course of human interstitial lung disease.
  • Lung function tests were not performed.
  • Control groups received plain saline rather than a vehicle containing the same sugars (sucrose and trehalose) as the treatment.
  • The unexpected scar-promoting response in the high-dose asbestos group needs dedicated long-term toxicology study.
  • Giving a human-derived product to rats may have triggered immune clearance that reduced its effect in later stages.

Topics

Medical terms in this study, explained in our Lexicon: Fibroblast, Inflammation, Bronchoalveolar Lavage (BAL), Cytokine, Collagen, Deposition, Biphasic Mesothelioma.

Related studies

• Conditioned medium from asbestos-exposed fibroblasts affects proliferation and invasion of lung cancer cell lines — S. Yu, H.H. Choi, et al. (2019)
• Role of Macrophages in Acute Lung Injury and Chronic Fibrosis Induced by Pulmonary Toxicants — D.L. Laskin, R. Malaviya, et al. (2019)
• Lung injury and expression of p53 and p16 in Wistar rats induced by respirable chrysotile fiber dust from four primary areas of China — Y. Zeng, Y. Cui, et al. (2018)
• Pemetrexed induced acute kidney injury in patients with non-small cell lung cancer: reversible and chronic renal damage — G. Rombolà, F. Vaira, et al. (2015)
• Human lung-derived mesenchymal stem cell-conditioned medium exerts in vitro antitumor effects in malignant pleural mesothelioma cell lines — L. Cortes-Dericks, L. Froment, et al. (2016)
• Safety, feasibility and therapeutic activity of intrapleural autologous lymphocyte conditioned medium followed by systemic recombinant interleukin-2 and interferon-alpha in a patient with malignant pleural mesothelioma — S. Duensing, H. Hamm, et al. (1997)

Browse more research in Biomedicines, or return to medical research.